James Hamilton - Jan 3, 2024 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Signature
/s/James Hamilton
Stock symbol
ARWR
Transactions as of
Jan 3, 2024
Transactions value $
-$1,333,529
Form type
4
Date filed
1/5/2024, 08:02 PM
Previous filing
Jul 5, 2023
Next filing
Jan 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Sale -$111K -3.5K -1.92% $31.81 179K Jan 3, 2024 Direct F1, F2, F3, F4
transaction ARWR Common Stock Sale -$74.8K -2.3K -1.29% $32.52 176K Jan 3, 2024 Direct F1, F2, F4, F5
transaction ARWR Common Stock Sale -$16.7K -500 -0.28% $33.30 176K Jan 3, 2024 Direct F1, F2, F4, F6
transaction ARWR Common Stock Award $0 +75K +42.63% $0.00 251K Jan 4, 2024 Direct F7
transaction ARWR Common Stock Sale -$61.2K -1.8K -0.72% $34.00 249K Jan 5, 2024 Direct F1, F2, F4, F8
transaction ARWR Common Stock Sale -$280K -8K -3.21% $34.94 241K Jan 5, 2024 Direct F1, F2, F4, F9
transaction ARWR Common Stock Sale -$440K -12.3K -5.12% $35.65 229K Jan 5, 2024 Direct F1, F2, F4, F10
transaction ARWR Common Stock Sale -$350K -10K -4.37% $35.00 219K Jan 5, 2024 Direct F1, F4, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 Partial disposition of RSUs to satisfy tax withholding obligations.
F3 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $31.22 to $32.19, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.
F5 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $32.21 to $32.93, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F6 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F7 Represents shares underlying restricted stock units with a grant date 01/04/24, which will vest in four equal annual installments.
F8 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $33.46 to $34.43, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F9 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $34.46 to $35.44, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F10 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.46 to $35.97, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F11 The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.06 , inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.